Cargando…

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans

GLP-1 receptor (GLP-1R) agonists may improve endothelial function (EF) via metabolic improvement and direct vascular action. The current study determined the effect of GLP-1R agonist exenatide on postprandial EF in type 2 diabetes and the mechanisms underlying GLP-1R agonist–mediated vasodilation. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koska, Juraj, Sands, Michelle, Burciu, Camelia, D’Souza, Karen M., Raravikar, Kalyani, Liu, James, Truran, Seth, Franco, Daniel A., Schwartz, Eric A., Schwenke, Dawn C., D’Alessio, David, Migrino, Raymond Q., Reaven, Peter D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477348/ https://www.ncbi.nlm.nih.gov/pubmed/25720388 http://dx.doi.org/10.2337/db14-0976

Ejemplares similares

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
por: Koska, Juraj, et al.
Publicado: (2010)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Exenatide (a GLP-1 agonist) improves the antioxidative potential of in vitro cultured human monocytes/macrophages
por: Bułdak, Łukasz, et al.
Publicado: (2015)

Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance
por: Cacciatori, Vittorio, et al.
Publicado: (2017)

Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide
por: Pinkney, Jonathan, et al.
Publicado: (2010)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Effects of GLP‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysis
por: Kelly, Michael, et al.
Publicado: (2022)

PEGylated-nanoliposomal clusterin for amyloidogenic light chain-induced endothelial dysfunction
por: Guzman-Villanueva, Diana, et al.
Publicado: (2017)

GLP‐1 Is a Coronary Artery Vasodilator in Humans
por: Clarke, Sophie J., et al.
Publicado: (2018)

Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
por: Ansar, Sameer, et al.
Publicado: (2011)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
por: Mansur, Sity Aishah, et al.
Publicado: (2019)

Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production
por: Sélley, Eszter, et al.
Publicado: (2014)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
por: Rosenstock, Julio, et al.
Publicado: (2013)

A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
por: Kayaniyil, Sheena, et al.
Publicado: (2016)

Proteomic Analysis of INS-1 Rat Insulinoma Cells: ER Stress Effects and the Protective Role of Exenatide, a GLP-1 Receptor Agonist
por: Kim, Mi-Kyung, et al.
Publicado: (2015)

Administration of the GLP-1 receptor agonist exenatide in rats improves functional recovery after spinal cord injury by reducing endoplasmic reticulum stress
por: Nomura, Satoshi, et al.
Publicado: (2023)

Is GLP‐1 a hormone: Whether and When?
por: D'Alessio, David
Publicado: (2016)

GLP-1 receptor agonist exenatide restores atypical antipsychotic clozapine treatment-associated glucose dysregulation and damage of pancreatic islet beta cells in mice
por: Hsu, Brend Ray-Sea, et al.
Publicado: (2016)

Acute Metabolic Effects of Exenatide in Patients With Type 1 Diabetes With and Without Residual Insulin to Oral and Intravenous Glucose Challenges
por: Ghazi, Tara, et al.
Publicado: (2014)

Monosialoganglioside‐Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins
por: Franco, Daniel A., et al.
Publicado: (2016)

Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models
por: Demkes, Evelyne J., et al.
Publicado: (2021)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin
por: De Lorenzo, C, et al.
Publicado: (2007)

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT)
por: Koska, Juraj, et al.
Publicado: (2013)

Differential Protective Effects of Exenatide, an Agonist of GLP-1 Receptor and Piragliatin, a Glucokinase Activator in Beta Cell Response to Streptozotocin-Induced and Endoplasmic Reticulum Stresses
por: Kim, Mi-Kyung, et al.
Publicado: (2013)

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial
por: Tonneijck, Lennart, et al.
Publicado: (2016)

The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial
por: Mitchell, James L, et al.
Publicado: (2023)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
por: Tatarkiewicz, K, et al.
Publicado: (2014)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
por: Borriello, M, et al.
Publicado: (2011)

Association of low fasting C-peptide levels with cardiovascular risk, visit-to-visit glucose variation and severe hypoglycemia in the Veterans Affairs Diabetes Trial (VADT)
por: Koska, Juraj, et al.
Publicado: (2021)

Exenatide at mealtimes in type 1 diabetes—no MAG1C with exenatide, or with other glucagon-like peptide-1 receptor agonists
por: Doggrell, Sheila A.
Publicado: (2020)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
por: Nauck, Michael A., et al.
Publicado: (2022)

Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcoma
por: Kang, Zhigang, et al.
Publicado: (2015)

Highly selective toxic and proapoptotic effects of two dimeric ribonucleases on thyroid cancer cells compared to the effects of doxorubicin
por: Spalletti-Cernia, D, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_fg27h908t62uthg0jc2o4m8n78